Why rNPV is Preferred for Biopharmaceutical Valuation
The typical time taken for an Investigational New Drug (IND) from submission to introduction in the market is around eight years. Such long periods of development make the Biopharma industry unique. A biopharma drug does not generate any revenue during the initial years of development resulting in significantly negative cash flows.
Biopharma drug development has to […]
